Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis

References

• ClarkMAFisherCJudsonIThomasJMSoft-tissue sarcomas in adultsN Engl J Med2005353770171116107623
   PubMed Web of Science ®Google Scholar
• CasaliPGBlayJYExperts ECECPoSoft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201021suppl 5v198v20320555081
   PubMed Web of Science ®Google Scholar
• DaigelerAZmarslyIHirschTLong-term outcome after local recurrence of soft tissue sarcoma: a retrospective analysis of factors predictive of survival in 135 patients with locally recurrent soft tissue sarcomaBr J Cancer201411061456146424481401
   PubMed Web of Science ®Google Scholar
• WeitzJAntonescuCRBrennanMFLocalized extremity soft tissue sarcoma: improved knowledge with unchanged survival over timeJ Clin Oncol200321142719272512860950
   PubMed Web of Science ®Google Scholar
• SleijferSOualiMvan GlabbekeMPrognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)Eur J Cancer2010461728319853437
   PubMed Web of Science ®Google Scholar
• CudmoreMJHewettPWAhmadSThe role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasisNat Commun2012397222828632
   PubMed Web of Science ®Google Scholar
• IvySPWickJYKaufmanBMAn overview of small-molecule inhibitors of VEGFR signalingNat Rev Clin Oncol200961056957919736552
   PubMed Web of Science ®Google Scholar
• HDAC Inhibition Overcomes Resistance to VEGFR inhibitors in solid tumorsCancer Discov201774350
   Web of Science ®Google Scholar
• SchutzFAChoueiriTKSternbergCNPazopanib: clinical development of a potent anti-angiogenic drugCrit Rev Oncol Hematol201177316317120456972
   PubMed Web of Science ®Google Scholar
• van der GraafWTBlayJYChawlaSPPazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialLancet201237998291879188622595799
   PubMed Web of Science ®Google Scholar
• SleijferSRay-CoquardIPapaiZPazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043)J Clin Oncol200927193126313219451427
   PubMed Web of Science ®Google Scholar
• Medscape [homepage on the Internet]FDA Approves Votrient for Advanced Soft Tissue Sarcoma2018 Available from: http://www.fda.govAccessed April 24, 2018
   Google Scholar
• MakiRGD’AdamoDRKeohanMLPhase II study of sorafenib in patients with metastatic or recurrent sarcomasJ Clin Oncol200927193133314019451436
   PubMed Web of Science ®Google Scholar
• StrumbergDRichlyHHilgerRAPhase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumorsJ Clin Oncol200523596597215613696
   PubMed Web of Science ®Google Scholar
• JhanwarSCChenQLiFPBrennanMFWoodruffJMCytogenetic analysis of soft tissue sarcomas. Recurrent chromosome abnormalities in malignant peripheral nerve sheath tumors (MPNST)Cancer Genet Cytogenet19947821381447828144
   PubMedGoogle Scholar
• JohnsonMRDeClueJEFelzmannSNeurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating functionMol Cell Biol19941416416458264632
   PubMed Web of Science ®Google Scholar
• MoriSSatohTKoideHNakafukuMVillafrancaEKaziroYInhibition of Ras/Raf interaction by anti-oncogenic mutants of neurofibromin, the neurofibromatosis type 1 (NF1) gene product, in cell-free systemsJ Biol Chem19952704828834288387499408
   PubMed Web of Science ®Google Scholar
• KeirSTMarisJMLockRInitial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing programPediatr Blood Cancer20105561126113320672370
   PubMed Web of Science ®Google Scholar
• MarisJMCourtrightJHoughtonPJInitial testing (stage 1) of sunitinib by the pediatric preclinical testing programPediatr Blood Cancer2008511424818293383
   PubMed Web of Science ®Google Scholar
• KeirSTMortonCLWuJKurmashevaRTHoughtonPJSmithMAInitial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing ProgramPediatr Blood Cancer201259358658822190407
   PubMed Web of Science ®Google Scholar
• ChowLQEckhardtSGSunitinib: from rational design to clinical efficacyJ Clin Oncol200725788489617327610
   PubMed Web of Science ®Google Scholar
• MahmoodSTAgrestaSVigilCEPhase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytomaInt J Cancer201112981963196921154746
   PubMed Web of Science ®Google Scholar
• StacchiottiSNegriTLibertiniMSunitinib malate in solitary fibrous tumor (SFT)Ann Oncol201223123171317922711763
   PubMed Web of Science ®Google Scholar
• StacchiottiSNegriTZaffaroniNSunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effectAnn Oncol20112271682169021242589
   PubMed Web of Science ®Google Scholar
• DemetriGDvan OosteromATGarrettCREfficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialLancet200636895441329133817046465
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med2007356212513417215530
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialJ Clin Oncol20102861061106820100962
   PubMed Web of Science ®Google Scholar
• RaymondEDahanLRaoulJLSunitinib malate for the treatment of pancreatic neuroendocrine tumorsN Engl J Med2011364650151321306237
   PubMed Web of Science ®Google Scholar
• RyanJLCarrollJKRyanEPMustianKMFiscellaKMorrowGRMechanisms of cancer-related fatigueOncologist200712suppl 12234
   PubMed Web of Science ®Google Scholar
• HensleyMLSillMWScribnerDRJrSunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II studyGynecol Oncol2009115346046519811811
   PubMed Web of Science ®Google Scholar
• HigginsJPAltmanDGGotzschePCThe Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsBMJ2011343d592822008217
   PubMed Web of Science ®Google Scholar
• YooKHKimHSLeeSJEfficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case seriesBMC Cancer20151515425885855
   PubMed Web of Science ®Google Scholar
• von MehrenMRankinCGoldblumJRPhase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomasCancer2012118377077621751200
   PubMed Web of Science ®Google Scholar
• Ray-CoquardIItalianoABompasESorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO)Oncologist201217226026622285963
   PubMed Web of Science ®Google Scholar
• SantoroAComandoneABassoUPhase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapyAnn Oncol20132441093109823230134
   PubMed Web of Science ®Google Scholar
• BramswigKPlonerFMartelASorafenib in advanced, heavily pretreated patients with soft tissue sarcomasAnticancer Drugs201425784885324667659
   PubMed Web of Science ®Google Scholar
• GeorgeSMerriamPMakiRGMulticenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomasJ Clin Oncol200927193154316019451429
   PubMed Web of Science ®Google Scholar
• LiTWangLWangHA retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinibInvest New Drugs201634670170627604635
   PubMed Web of Science ®Google Scholar
• LiuBDingFZhangDWeiGHRisk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysisCancer Chemother Pharmacol201780348749528695268
   PubMed Web of Science ®Google Scholar
• MasseyPROkmanJSWilkersonJCowenEWTyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literatureSupport Care Cancer20152361827183525471178
   PubMed Web of Science ®Google Scholar
• EscudierBPortaCBonoPRandomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES StudyJ Clin Oncol201432141412141824687826
   PubMed Web of Science ®Google Scholar
• SantoniMContiAMassariFTreatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trialsInt J Cancer2015136111024415642
   PubMed Web of Science ®Google Scholar
• CroomKFPerryCMImatinib mesylate: in the treatment of gastrointestinal stromal tumoursDrugs2003635513522 discussion 523–51412600228
   PubMed Web of Science ®Google Scholar
• RutkowskiPWozniakASwitajTAdvances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberansSarcoma2011201195913221559214
   PubMedGoogle Scholar
• RutkowskiPVan GlabbekeMRankinCJImatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trialsJ Clin Oncol201028101772177920194851
   PubMed Web of Science ®Google Scholar
• KerobDPorcherRVerolaOImatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patientsClin Cancer Res201016123288329520439456
   PubMed Web of Science ®Google Scholar
• StacchiottiSPedeutourFNegriTDermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinibInt J Cancer201112971761177221128251
   PubMed Web of Science ®Google Scholar